<?xml version="1.0" encoding="UTF-8"?>
<ref id="BST-47-1757C95">
 <label>95</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Liu Y</surname>
    <given-names>Z.X.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Zhou</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Nan</surname>
    <given-names>X.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Chen</surname>
    <given-names>X.</given-names>
   </name> and 
   <name name-style="western">
    <surname>Zhang</surname>
    <given-names>X.</given-names>
   </name>
  </person-group> (
  <year>2017</year>) 
  <article-title>Mitochondrial-targeting lonidamine-doxorubicin nanoparticles for synergistic chemotherapy to conquer drug resistance</article-title>. 
  <source>ACS Appl. Mater Interfaces</source>
  <volume>9</volume>, 
  <fpage>43498</fpage>â€“
  <lpage>43507</lpage>
  <pub-id pub-id-type="doi">10.1021/acsami.7b14577</pub-id>
  <pub-id pub-id-type="pmid">29171954</pub-id>
 </mixed-citation>
</ref>
